Background: Protease inhibitor monotherapy is associated with more frequent episodes of viral rebounds above\n50 copies/mL than triple therapy. Objective: To evaluate if, compared to triple-drug therapy, protease inhibitor\nmonotherapy is associated with increased levels of inflammatory/procoagulant markers and more frequent plasma\nresidual viremia detection.\nMethods: In this cross-sectional study, we included patients treated for ? 1 year with darunavir/ritonavir or lopinavir/\nritonavir as monotherapy (n = 72) or with two nucleos(t)ides (n = 74). All samples were tested for CRP, IL-6, fibrinogen\nand D-dimer. Residual viremia was determined using an ultrasensitive qualitative nested-PCR of the HIV pol gene with\na limit of detection of 1 copy of HIV-RNA.\nResults: We found no differences in levels of inflammatory/procoagulant markers or in the proportion of patients with\nplasma residual viremia detection by treatment group.\nConclusion: The long-term treatment with protease inhibitor monotherapy in the setting of routine clinical practice is\nnot associated with a higher prevalence of plasma residual viremia or more elevated inflammatory/procoagulant\nmarkers levels than triple drug therapy.
Loading....